Bulk Inquiry
BIRB 796
- BIRB0796 - Doramapimod
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C31H37N5O3
- MW: 527.66
Description
BIRB 796 (Doramapimod) is a highly potent, selective and orally active p38 mitogen-activated protein kinase (p38 MAPK) inhibitor. BIRB 796 exhibits high affinity for all four p38 isoforms and is more potent than SB 203580 (Axon 1363) against p38α and p38β MAPK, resulting in effective suppression of p38-dependent inflammatory signaling pathways.
The p38 MAPK pathway regulates inflammatory cytokine production, cellular stress responses, differentiation, and survival. BIRB 796 suppresses the production of pro-inflammatory cytokines including TNF-α and IL-1β and has been extensively investigated in inflammatory disease models. In stem cell research, inhibition of p38 signaling has been shown to support pluripotency, enhance cellular reprogramming, promote self-renewal, and improve expansion of stem and progenitor cell populations. BIRB 796 is therefore widely used in stem cell biology, regenerative medicine, and developmental biology studies. Additionally, BIRB 796 has demonstrated antitumor activity in preclinical cancer models through inhibition of tumor cell proliferation and induction of apoptosis.
Key Features
- Highly potent and selective p38 MAPK inhibitor
- More potent than SB 203580 against p38α and p38β
- Suppresses TNF-α and IL-1β production
- Suppresses tumor cell proliferation and exerts cytotoxic effects on multiple myeloma
- Supports stem cell self-renewal and maintains naive pluripotency
Applications
- p38 MAPK signaling research
- Inflammation and cytokine signaling studies
- Stem cell maintenance and pluripotency research
- Cellular reprogramming and regenerative medicine studies
- Cancer biology and apoptosis investigations
*Promotion: BIRB 796 is also part of Inhibitor Set(s):
| Naive Stem Cell NHSM inhibitor Set (Axon 5010) |
More Information
| Parent CAS No. | 285983-48-4 |
|---|---|
| Chemical Name | 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| SMILES | N1(N=C(C(C)(C)C)C=C1NC(=O)NC1C=CC(OCCN2CCOCC2)=C2C=CC=CC=12)C1C=CC(C)=CC=1 |
| MFCD | MFCD09752957 |
| InChi | InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37) |
| InChiKey | MVCOAUNKQVWQHZ-UHFFFAOYSA-N |
| CID | 156422 |
| Short Description | p38 MAPK inhibitor |
References
- C Pargellis et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
- Y Kuma et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Boil. Chem. 2005, 280, 19472-19479.
- J Bain et al. The selectivity of protein kinase inhibitors: a further update.Biochem J. 2007, 408, 297–315.
- List of publications using BIRB 796 (Axon 1358) purchased from Axon Medchem
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1122 | SL 327 |
From $88.00 |
| 1223 | PD98059 |
From $88.00 |
| 1357 | SD 169 |
From $66.00 |
| 1363 | SB 203580 |
From $104.50 |
| 1364 | SB 202190 |
From $104.50 |
| 1365 | PD169316 |
From $104.50 |
| 1366 | LY 294002 |
From $77.00 |
| 1368 | PD184352 |
From $88.00 |
| 1393 | Gefitinib |
From $77.00 |
| 1399 | AZD7762 hydrochloride |
From $66.00 |
| 1406 | CP 101606 mesylate |
From $93.50 |
| 1408 | PD0325901 |
From $55.00 |
| 1409 | KO 143 |
From $77.00 |
| 1459 | GDC 0879 |
From $77.00 |
| 1461 | Cediranib |
From $77.00 |
| 1465 | SB 203580 hydrochloride |
From $77.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1516 | AZD6244 |
From $66.00 |
| 1527 | XAV939 |
From $88.00 |
| 1545 | AZ 628 |
From $88.00 |
| 1603 | Rolofylline |
From $99.00 |
| 1613 | MDV 3100 |
From $77.00 |
| 1621 | XMD 8-92 trifluoroacetate |
From $77.00 |
| 1631 | Vildagliptin |
From $66.00 |
